Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

nary tract symptoms (LUTS) are more complex conditions than once thought. While previous research on BPH etiology tended to focus on testosterone and other hormones, more recent research suggests other factors - including inflammation, various growth factors, and adrenoreceptors - actually may play a greater role in the development of BPH and LUTS.

BPH is associated with LUTS, including: frequent urination, a sudden, uncontrollable urge to urinate, waking at night to urinate (nocturia), difficulty starting a urine stream (hesitancy and straining), decreased strength of the urine stream (weak flow), feeling that the bladder is not completely empty, an urge to urinate again soon after urinating and pain during urination (dysuria). Currently available therapies may improve symptoms to some degree, but often come with sexual and other side effects.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic c
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
(Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 a2z Inc. ... ChirpE Mobile App, AACC Pathfinder, in its 2014 ... AACC’s annual meeting is planned for July 29-31, 2014 ... place to be to connect with global leaders in ... management, and other areas of breaking science in laboratory ...
(Date:7/22/2014)... July 22, 2014 The Board of Directors of ... has declared a quarterly dividend of 54.5 cents per common ... on September 9, 2014. The indicated annual dividend rate is ... BD is a leading medical technology company that partners with ... pressing and evolving health needs. Our innovative solutions are focused ...
Breaking Biology Technology:BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... NEW HAVEN, Conn., Sept. 9 Rib-X ... company focused on the,discovery and development of ... announced today the formation of its,Clinical Advisory ... disease,specialists, will provide oversight and counsel on ...
... Expert Physician Commentaries ... and Practice Developments, Expert Physician Panel Selects ... Treatment as Year,s Most Influential Oncology Development, ... (http://www.OncologySTAT.com ),a free web site featuring high-quality, scientifically ...
... Clinical Programs, With Three Bavituximab Phase ... -, - Updated Initial Data from Bavituximab Plus Docetaxel Phase II Breast, Cancer Trial ... ... Defense Threat Reduction Agency ...
Cached Biology Technology:Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 2Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 3OncologySTAT Advisors Name Year's Top Developments in Cancer Treatment and Research 2OncologySTAT Advisors Name Year's Top Developments in Cancer Treatment and Research 3OncologySTAT Advisors Name Year's Top Developments in Cancer Treatment and Research 4Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 2Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 3Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 4Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 5Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 6Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 7Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 8Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 9Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 10
(Date:7/23/2014)... TORONTO, July 23, 2014 Migratory songbirds are disappearing, ... as climate change, loss of habitat, acid rain and ... remained missing: where do these birds go once they ... be encountering along the way? , To answer this ... have created the first ever migratory connectivity map produced ...
(Date:7/23/2014)... fly Chrysomya megacephala is commonly found in ... determine the time of death, referred to as the ... of C. megacephala from Tamil Nadu is ... and molecular characterization through generation of DNA barcoding. This ... open access Biodiversity Data Journal . , ...
(Date:7/23/2014)... potential for clinical use of induced pluripotent stem ... previously been hindered by the risk of dysregulated ... ability to use etoposide treatment to halt teratoma ... disease, specifically acute myocardial infarction, is demonstrated in ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Biology News(10 mins):York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2Dead body feeding larvae useful in forensic investigations 2
... LAS VEGAS , Jan. 6, 2014  LG Electronics (LG) ... Heart Rate Earphones, two wearable products that mark the company,s ... Consumer Electronics Show (CES) in Las Vegas ... devices so that monitoring one,s health requires no additional effort ...
... the food industry at sublethal doses may be endangering, ... in bacteria and enhancing their ability to form harmful ... in Applied and Environmental Microbiology . This is ... The study was designed to test whether exposing ...
... in small proteins that help convey electrical signals throughout the ... to results of a new Johns Hopkins study study published ... in December using spider, scorpion and sea anemone venom. ... sodium channels that are vital to our well-beingthey trigger action ...
Cached Biology News:LG Jumps Into Fitness Tech At CES With Lifeband Touch And Heart Rate Earphones 2LG Jumps Into Fitness Tech At CES With Lifeband Touch And Heart Rate Earphones 3Improper use of biocides in food production may endanger public health 2Tiny proteins have outsized influence on nerve health 2Tiny proteins have outsized influence on nerve health 3
... a platform for fully automated systems for ... easily be configured for applications ranging from ... allows closed loop screening, which means it ... generating, cherry picking and follow up studies ...
... devices for the fast and reliable clarification/filtration of ... 500 l. They can be used in fixed ... Features: High-flux Polyethersulphonemembrane 0.8 ... volume ( Fast and reproducible performance ...
... Prelude Workstation fully automates pharmaceutical sample ... extraction, sample transfer, mixing and dilutions. ... UV detection. The Prelude performs these ... CFR Part 11. The Prelude ...
... in any standard fixed-angle microcentrifuge rotor ... g.,Spin- centrifuge tube filters consist of ... centrifuge tube. They filter by centrifugation ... sample preparation, removal of cells from ...
Biology Products: